116371-67-6
116371-67-6
Chemical Structure
Gemcitabine monophosphate
Synonym(s): Gemcitabine 5′-phosphate
- CAS No.: 116371-67-6
- Formula:C9H12F2N3O7P
- Molecular Weight:343.18
IUPAC Name: ((2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4,4-difluoro-3-hydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate
InChIKey: KNTREFQOVSMROS-QPPQHZFASA-N
SMILES: OP(OC[C@@H]1[C@@H](O)C(F)(F)[C@H](N2C=CC(N)=NC2=O)O1)(O)=O
Biological Activity: Gemcitabine monophosphate (Gemcitabine 5′-phosphate) is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate has a synergistic anti-cancer effect and can be delivered by formulating it into nanoparticles[1][2].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Gemcitabine monophosphate | 99.98% | Gemcitabine monophosphate (Gemcitabine 5′-phosphate) is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate has a synergistic anti-cancer effect and can be delivered by formulating it into nanoparticles. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Gemcitabine monophosphate (Standard) | ≥98% | Gemcitabine monophosphate (Standard) is the analytical standard of Gemcitabine monophosphate (HY-108932). This product is intended for research and analytical applications. Gemcitabine monophosphate (Gemcitabine 5′-phosphate) is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate has a synergistic anti-cancer effect and can be delivered by formulating it into nanoparticles. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhang Y, et al. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol Ther. 2013 Aug;21(8):1559-69. [Content Brief]
- [2]. Miao L, et al. Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer. Adv Funct Mater. 2014 Nov 12;24(42):6601-6611. [Content Brief]
